Informational only — Not medical advice. Always consult a licensed healthcare provider.

MedBD
বাং
Community data Updated 2 months ago

Thalidomide

Immunosuppressant Prescription
Check interactions
🌐 বাংলায় দেখুন

Indications

Midothal, combined with dexamethasone, is used to treat patients newly diagnosed with multiple myeloma (MM). Midothal is also used to treat the skin symptoms of moderate to severe erythema nodosum leprosum (ENL) flare-ups, and to help prevent and control these skin symptoms from recurring as a maintenance therapy.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Cellular effects of thalidomide occur through its binding target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. The medicine has immunomodulatory, anti-inflammatory and antiangiogenic properties. In vitro studies and clinical trials suggest that its immune effects may stem from suppressing excess production of tumor necrosis factor-alpha (TNF-a) and reducing certain cell surface adhesion molecules that leukocytes use to migrate. Other anti-inflammatory and immunomodulatory actions may include reduced macrophage involvement in prostaglandin synthesis, along with changes in interleukin-10 and interleukin-12 production by peripheral blood mononuclear cells. In patients with multiple myeloma, treatment with thalidomide is accompanied by a rise in circulating natural killer cells and higher plasma levels of interleukin-2 and interferon-gamma. Among the cellular processes involved in angiogenesis, thalidomide is thought to inhibit the proliferation of endothelial cells.

Pregnancy & Breastfeeding

Pregnancy: Based on the mechanism of action, human and animal data, thalidomide can cause embryo-fetal harm when administered to a pregnant female and is contraindicated during pregnancy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus. If pregnancy does occur during treatment, the drug should be immediately discontinued.Lactation: There is no information regarding the presence of thalidomide in human milk, the effects of thalidomide on the breastfed child, or the effects of thalidomide on milk production. Because many drugs are excreted in human milk and because of the potential for adverse reactions in a breastfed child from thalidomide, women should be advised not to breastfeed during treatment with thalidomide.Females and Males of Reproductive Potential-Pregnancy Testing: Females of reproductive potential must have 2 negative pregnancy tests before initiating Thalidomide. The first test should be performed within 10-14 days, and the second test within 24 hours prior to prescribing Thalidomide. Once treatment has started and during dose interruptions, pregnancy testing for females of reproductive potential should occur weekly during the first 4 weeks of use, then pregnancy testing should be repeated every 4 weeks in females with regular menstrual cycles. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks.Contraception: Females of reproductive potential must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously. Contraception must begin 4 weeks prior to initiating treatment with Thalidomide, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of Thalidomide therapy.Males: Thalidomide is present in the semen of males who take Thalidomide. Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking Thalidomide, during dose interruptions and for up to 28 days after discontinuing Thalidomide.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Multiple Myeloma: The recommended dosing of thalidomide in combination with dexamethasone is 200 mg once daily, taken orally with water in 28-day treatment cycles, preferably at bedtime and at least 1 hour after the evening meal. Erythema Nodosum Leprosum: The recommended dosing of thalidomide for an episode of cutaneous ENL is 100 to 300 mg per day, taken orally once daily with water, preferably at bedtime and at least 1 hour after the evening meal. Patients weighing less than 50 kilograms should begin dosing at the low end of this range. A higher dosage range should be considered for patients with a severe cutaneous ENL reaction, or for those who have previously needed higher doses to control the reaction (possibly up to 400 mg per day), taken once daily at bedtime or in divided doses with water, at least 1 hour after meals. Using corticosteroids alongside thalidomide should be considered for patients with moderate to severe neuritis linked to a severe ENL reaction. Steroid use can be tapered and stopped once the neuritis has improved. The higher dosage of thalidomide should be continued until signs and symptoms of the active reaction have subsided, usually for at least 2 weeks. Patients can then be tapered off the medication in 50 mg decrements every 2 to 4 weeks.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.